Stay updated with breaking news from Intercept Pharmaceutical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Akero Therapeutics’ experimental NASH drug, efruxifermin, met the main and secondary goals of Phase 2b clinical trial. The biotech will still need to show that the drug’s efficacy can hold up in a pivotal study, but the results so far are a positive sign for the NASH field, which has been marred by clinical trial failures.
Two years after the stinging FDA rejection of its drug for the fatty liver disease NASH, Intercept Pharmaceuticals has more safety and efficacy data from a pivotal study that could support resubmission of a new drug application. The biotech said it will meet with the FDA later this month.
Advanz Pharma, which is backed by Nordic Capital, has agreed to acquire Intercept Pharmaceutical Inc.'s business in Europe, Canada and all other markets outside of the U.S.
Binary events on the way could send these drugmaker stocks through the roof, or push them down in the dirt.
Binary events on the way could send these drugmaker stocks through the roof, or push them down in the dirt.